ALYGLO Trademark

Trademark Overview

On Friday, September 4, 2020, a trademark application was filed for ALYGLO with the United States Patent and Trademark Office. The USPTO has given the ALYGLO trademark a serial number of 90160114. The federal status of this trademark filing is REGISTERED as of Tuesday, November 26, 2024. This trademark is owned by Green Cross Corporation. The ALYGLO trademark is filed in the Pharmaceutical Products category with the following description:

Blood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin reparations, namely, pharmaceutical immunoglobulin preparations for treatment of primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich Syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP); all the foregoing for patient treatment by injection or in liquid form by health professional
alyglo

General Information

Serial Number90160114
Word MarkALYGLO
Filing DateFriday, September 4, 2020
Status700 - REGISTERED
Status DateTuesday, November 26, 2024
Registration Number7580083
Registration DateTuesday, November 26, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 20, 2021

Trademark Statements

Goods and ServicesBlood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin reparations, namely, pharmaceutical immunoglobulin preparations for treatment of primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich Syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP); all the foregoing for patient treatment by injection or in liquid form by health professional

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 9, 2020
Primary Code005
First Use Anywhere DateMonday, July 8, 2024
First Use In Commerce DateMonday, July 8, 2024

Trademark Owner History

Party NameGC BIOPHARMA CORP.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressYongin-si, Gyeonggi-do 16924
KR
Party NameGC BIOPHARMA CORP.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressYongin-si, Gyeonggi-do 16924
KR
Party NameGreen Cross Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressYongin-si, Gyeonggi-do 16924
KR
Party NameGreen Cross Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressYongin-si, Gyeonggi-do 16924
KR

Trademark Events

Event DateEvent Description
Friday, October 9, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 8, 2020NEW APPLICATION ENTERED
Tuesday, January 12, 2021ASSIGNED TO EXAMINER
Wednesday, January 13, 2021PRIORITY ACTION WRITTEN
Wednesday, January 13, 2021PRIORITY ACTION E-MAILED
Wednesday, January 13, 2021NOTIFICATION OF PRIORITY ACTION E-MAILED
Wednesday, March 10, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 10, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 11, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 12, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 31, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 20, 2021PUBLISHED FOR OPPOSITION
Tuesday, April 20, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, May 6, 2021EXTENSION OF TIME TO OPPOSE RECEIVED
Monday, October 18, 2021OPPOSITION INSTITUTED NO. 999999
Thursday, January 20, 2022OPPOSITION TERMINATED NO. 999999
Thursday, January 20, 2022OPPOSITION DISMISSED NO. 999999
Thursday, January 20, 2022TTAB RELEASE CASE TO TRADEMARKS
Wednesday, January 26, 2022TEAS POST PUBLICATION AMENDMENT RECEIVED
Wednesday, February 2, 2022ASSIGNED TO PETITION STAFF
Monday, February 7, 2022CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Tuesday, March 1, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, March 24, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, March 24, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, March 24, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Thursday, March 24, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 2, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, August 2, 2022SOU EXTENSION 1 FILED
Tuesday, August 2, 2022SOU EXTENSION 1 GRANTED
Thursday, August 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, February 22, 2023SOU EXTENSION 2 FILED
Wednesday, February 22, 2023SOU EXTENSION 2 GRANTED
Friday, February 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 14, 2024SOU EXTENSION 4 FILED
Monday, August 28, 2023SOU TEAS EXTENSION RECEIVED
Monday, August 28, 2023SOU EXTENSION 3 FILED
Monday, August 28, 2023SOU EXTENSION 3 GRANTED
Wednesday, August 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 14, 2024SOU TEAS EXTENSION RECEIVED
Thursday, February 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 19, 2024USE AMENDMENT FILED
Monday, August 19, 2024TEAS STATEMENT OF USE RECEIVED
Wednesday, February 14, 2024SOU EXTENSION 4 GRANTED
Wednesday, April 3, 2024ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Thursday, October 24, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, October 24, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, October 24, 2024STATEMENT OF USE PROCESSING COMPLETE
Wednesday, October 23, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, November 26, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, November 26, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

alyglo immune immunoglobulin deficiency bacterial syndrome treatment disease agammaglobulinemia namely inflammatory